The Federal Trade Commission recently decided to swing its weight at Hims & Hers. The agency, along with partners in Utah and California, claims the telehealth giant tricked customers into subscriptions and leaked private medical data to advertisers.
If you ask CEO Andrew Dudum, though, the regulators are chasing headlines rather than facts.
He’s not just sitting on his hands. While the legal battle drags on, Dudum is doubling down on a future where artificial intelligence does the heavy lifting in patient care. He expects AI-powered "health coaches" to hit the market in about a year. His bet is simple: keep patients on their meds, and the business wins.
Where The Regulators Get It Wrong
The FTC’s complaint isn't subtle. They allege that Hims & Hers made it intentionally difficult for users to cancel subscriptions, hidden away like a secret in a maze of buttons. They also point to the company sharing "sensitive health information" with platforms like Meta and Snap.
To the government, this is a clear-cut case of deceptive business practices. They see an aggressive company putting profit growth ahead of patient privacy and clear billing.
Dudum sees it differently. He characterizes the company as an "active disruptor." In his view, the friction the FTC is complaining about is just part of the messy process of dragging a stagnant healthcare industry into the modern age. He’s essentially arguing that the regulator wants a scalp—a high-profile win—rather than an actual solution to the problems they’ve identified.
It’s the classic tension between a Silicon Valley "move fast and break things" philosophy and the slow, deliberate pace of federal oversight.
Why Medication Adherence Is The Real Game
Look past the court filings, and you find the real strategy. Most patients prescribed drugs for chronic conditions drop off within a year. They forget. They get discouraged. They quit.
That’s where Dudum’s next big move comes in. He wants to deploy AI coaches that act as a digital hand-holder. Imagine a system that doesn’t just remind you to take your medication but actually checks in on your side effects. If a dose is making you feel rough, the AI identifies the problem, loops in a provider, and gets your prescription tweaked.
The goal? Doubling or tripling medication adherence rates.
He’s talking about connecting this system to everything: your at-home blood tests, your smart scale, your wearable sensors, and even Bluetooth-enabled medicine bottles that report when you’ve actually opened the cap. If this sounds like surveillance, that's because it sort of is. But for someone struggling to manage a condition, it’s also a lifeline.
The Data Privacy Tightrope
The elephant in the room is how the company balances this data-hungry future with the privacy concerns raised by the FTC.
If you’re going to have an AI coach monitoring your blood glucose and checking when you open your pill bottle, that data is intensely private. The FTC’s lawsuit effectively argues that Hims & Hers hasn't been responsible stewards of less sensitive information. If they can’t be trusted with website click data, how can they be trusted with the deep health insights needed for AI-driven care?
Dudum’s defense is that the company is building a platform where success for the business is tied directly to the patient’s health. He argues that you can't build a massive, long-term business if your customers don't actually get better.
Moving Past The Headlines
Investors are understandably nervous. Hims & Hers is in a "hold" pattern for many on Wall Street as the legal risk looms. The Q2 earnings report showed revenue growth, but the costs associated with fighting the FTC are starting to show up on the balance sheet.
For the average user, this means two things:
- Be skeptical of the subscription model. Don't assume that signing up for a "consultation" means you're going to talk to a human who will decide your treatment. Read the terms, check the refill dates, and know exactly how to cancel before you hand over your credit card.
- Watch the AI integration closely. Telehealth is shifting from "get a prescription online" to "manage my chronic condition with smart tools." That transition is going to involve a massive amount of personal data.
The FTC wants to hold a company accountable for past actions. The company wants to reinvent how we experience healthcare. Both can be true at the same time.
If you're looking for better health outcomes, keep your eyes on how these tech-heavy platforms actually handle the data they collect. Convenience is nice, but it shouldn't come at the cost of your privacy or your wallet. If a service makes it impossible to leave, it’s not a service—it’s a trap. Keep your subscriptions lean and watch your data footprint.
The future of medicine might be an app, but you’re still the one who has to live with the consequences of how it uses your information.
